Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EQL Pharma AB ( (SE:EQL) ) has issued an update.
EQL Pharma’s key melatonin product Mellozzan has received marketing authorization in Italy, where it will be launched through licensing partner Italfarmaco, one of the country’s leading pharmaceutical groups. The Italian rollout, expected around the end of fiscal 2026/27 or early 2027/28, marks Mellozzan’s second greenfield market after Germany and is set to expand EQL’s European footprint and brand-building efforts in pediatric ADHD-related sleep disorders and adult jet lag.
Positive reception in Germany from doctors and patients gives EQL confidence that Mellozzan can gain traction in Italy as well, supported by Italfarmaco’s strong local sales and marketing infrastructure. The approval strengthens EQL’s strategy of leveraging partners to commercialize specialized generics in major European markets, potentially enhancing long-term prescription volumes and reinforcing its position in the niche sleep-disorder segment.
More about EQL Pharma AB
EQL Pharma AB is a Lund-based pharmaceutical company focused on developing and selling niche generic prescription drugs, including hospital products, primarily in the Nordic region and selected European markets. The company has more than 47 approved niche generics with limited competition and collaborates extensively with contract manufacturers and pharma partners in the EU and Asia.
Average Trading Volume: 29,855
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.52B
For an in-depth examination of EQL stock, go to TipRanks’ Overview page.